SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Bioterrorism

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who started this subject10/25/2001 2:43:40 PM
From: tuck  Read Replies (1) of 891
 
This PR is from a dubious OTC:BB company, more likely a short than long candidate, but it has some links to the studies regarding its product. Thus SI BioterrorFreaks are free to decorticate them:

>>LAS VEGAS, Oct 25, 2001 (BUSINESS WIRE) -- TRSG Corp. (OTC BB: TSGO chart, msgs) a majority-owned subsidiary of Gateway Distributors Ltd. (OTC BB: GTWY chart, msgs), Thursday announced it has begun the sales and marketing of hand-held, low-cost devices used to detect the presence of biological agents such as Bacillus Anthraci (commonly referred to as Anthrax) as well as many other biological agents.

These detection devices are designed specifically for home or small office use and are priced between $50 and $100 per unit.

The company's new Biological Agent Detection Product utilizes UV-A waves or waves in the 320 to 380 nm range, commonly referred to as black light or wood's light, that have been determined to not cause sunburn to human skin though the use of eye protection is recommended during use. These products are for detection purposes only and are not intended as a treatment or cure for any specific disease.

Ongoing research is being conducted at this time to verify the product's effectiveness in the use of identifying the presence of a wide range of biological agents such as Becillus Anthraci, which is currently making headlines across the country. Independent research laboratories are conducting this research.

Additional information regarding these studies can be found on the following Web sites: potomacinstitute.org potomacinstitute.org hhmi.org hantavirus.htm cdc.gov

TRSG Corp. ("TRSG" or "the company") believes that it will be able to use its domestic as well as international marketing structure to market and distribute this new line of products directly to the consumer and office market place using its more then 14,000 independent distributors.

The company believes it will benefit from the current need of business and consumers to seek higher levels of protection from potential biological agent contamination from unknown parties and can effectively compete with companies such as, Cepheid (Nasdaq: CPHD chart, msgs) and Bruker Daltonics (Nasdaq: BDAL chart, msgs).

With target retail prices of between $50 and $100 per unit, these hand-held products will offer consumers and small businesses a viable solution to address current Anthrax concerns. This additional product line will provide an area of diversification for the company from its health and dietary products currently being marketed and provide an additional source for income for the company and its marketing forces.

Gateway Distributors Ltd. and its subsidiary TRSG are in the business of selling health and environmentally safe products throughout North America, Russia, and Japan. TRSG believes sales of these products will have a significant positive effect on the overall company's revenues. Ordering information and procedures can be found on the company's Web site www.rightsolution.com.

A number of statements contained in this press release are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

These forward-looking statements involve a number of risks and uncertainties, including the timely development, and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions and the ability to secure additional sources of financing.

The actual results that TRSG may achieve could differ materially from any forward-looking statements due to such risks and uncertainties.<<

snip, emphasis mine.

My knee-jerk response (as someone with rusting familiarity with solar radiation measurement (emphasis on U.V. and visible)) is that they are likely to get a fair number of false positives, but I haven't looked at the studies myself, yet. Emphasis where it is to highlight that they're selling the product, but the research to prove it works is "ongoing." Will cross post to a short thread or two, they should love this one.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext